Smaller molecular weight over ADCs

Compared to antibody-drug conjugates (ADCs), these smaller conjugate drugs have multiple advantages, such as lower molecular weight, high affinity and selectivity, enhanced tumor tissue penetration, reduced non-tumor tissue distribution, lower systemic exposure, wider therapeutic window, and improved safety.

Better tumor penetration

Compared to ADCs, the PDCs and NDCs developed by Conjustar leverage their smaller molecular size to better penetrate tumor tissues, while also having a more concentrated distribution in the body, reducing side effects on normal tissues. These characteristics enable these novel drug conjugates to exhibit superior performance in both efficacy and safety.

Reduced non-target distribution, improved safety

Conjustar is focused on applying cutting-edge biotechnology to continuously advance the research and development of these innovative small molecule drug conjugates, striving to provide patients with safer and more effective treatment options.